Gsk Plc-spon Adr. Share Price Today
(NASDAQ: GSK)

Name: Gsk Plc-spon Adr. Share Price Today (NASDAQ: GSK) - Gsk Plc-spon Adr. Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Gsk Plc-spon Adr. share price is $36.96 & ₹3,201.51 as on 21 Feb 2025, 2.30 'hrs' IST

$36.96

▲

0.42

(1.15%)

Market is closed - opens 8 PM, 21 Feb 2025

View live Gsk Plc-spon Adr. share price in Dollar and Rupees. Guide to invest in Gsk Plc-spon Adr. stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Gsk Plc-spon Adr., along with analyst recommendations, forecasts, and comprehensive financials.

Gsk Plc-spon Adr. share price movements

Today's Low: $36.63
Today's High: $37.22
$36.96
0.89%
Downside
Day's Volatility :1.57%
Upside
0.69%
52 Weeks Low: $31.72
52 Weeks High: $45.93
$36.96
14.19%
Downside
52 Weeks Volatility :30.94%
Upside
19.52%

Gsk Plc-spon Adr. (GSK) Returns

Period	Gsk Plc-spon Adr.	Russel 2000	Index (Russel 2000)
3 Months	8.83%	0.0%	0.0%
6 Months	-13.3%	0.0%	0.0%
1 Year	-12.33%	0.0%	0.0%
3 Years	-30.74%	-12.0%	-12.0%

Gsk Plc-spon Adr. (GSK) Key Statistics

in dollars & INR

Previous Close	$36.54
Open	$36.72
Today's High	$37.2177
Today's Low	$36.632
Market Capitalization	$74.6B
Today's Volume	$6.2M
52 Week High	$45.925
52 Week Low	$31.715
Revenue TTM	$31.4B
EBITDA	$9.2B
Earnings Per Share (EPS)	$1.57
PE Ratio	23.27
Dividend Yield	4.25%
Profit Margin	8.21%
Quarterly Earnings Growth YOY	0.17%
Return On Equity TTM	22.8%

How to invest in Gsk Plc-spon Adr. Stock (GSK) from India?

It is very easy for Indian residents to invest directly in Gsk Plc-spon Adr. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Gsk Plc-spon Adr. stock in both Indian Rupees (INR) and US Dollars (USD). Search for Gsk Plc-spon Adr. or GSK on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Gsk Plc-spon Adr. or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Gsk Plc-spon Adr. shares which would translate to 0.023 fractional shares of Gsk Plc-spon Adr. as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Gsk Plc-spon Adr., in just a few clicks!

Returns in Gsk Plc-spon Adr. (GSK) for Indian investors in Rupees

The Gsk Plc-spon Adr. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Gsk Plc-spon Adr. investment value today

Current value as on today

₹92,176

Returns

₹7,824

(-7.82%)

Returns from Gsk Plc-spon Adr. Stock

₹12,334 (-12.33%)

Dollar Returns

₹4,510 (+4.51%)

Indian investors sentiment towards Gsk Plc-spon Adr. (GSK)

41%

Period: Jan 21, 2025 to Feb 20, 2025. Change in 30 Days versus previous period

Search interest for Gsk Plc-spon Adr. Stock from India on INDmoney has increased by 41% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Gsk Plc-spon Adr.

Dodge & Cox
3.35%
FMR Inc
1.42%
PRIMECAP Management Company
1.24%
JTC Employer Solutions Trustee Ltd
0.99%
Fisher Asset Management, LLC
0.92%
Morgan Stanley - Brokerage Accounts
0.39%

Analyst Recommendation on Gsk Plc-spon Adr.

Buy

60%Buy

30%Hold

9%Sell

Based on 33 Wall street analysts offering stock ratings for Gsk Plc-spon Adr.(by analysts ranked 0 to 5 stars)

Based on 33 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Gsk Plc-spon Adr. Stock (GSK)

What analysts predicted

Upside of 17.48%

Target:

$43.42

Current:

$36.96

Insights on Gsk Plc-spon Adr. Stock (Ticker Symbol: GSK)

Price Movement
In the last 7 days, GSK stock has moved up by 2.2%
Increasing Revenue
GSK Plc Sponsored ADR has shown consistent revenue growth over the last three quarters. The revenue has increased from $7.36 billion to $8.01 billion, resulting in an average increase of 4.1% per quarter.
Decreasing Net Profit
GSK Plc's Sponsored ADR has experienced a significant decline in net profit over the last two quarters. The net profit fell from $1.17 billion to -$58 million, resulting in an average decrease of 104.9% per quarter. This indicates that the company has struggled financially in recent times.
GSK vs LLY (1 yr)
In the last 1 year, Eli Lilly And Company has given 17.1% return, outperforming this stock by 29.0%
GSK vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 263.3% return, outperforming this stock by 294.6%
Price to Sales
GSK Plc's Price-to-Sales Ratio indicates that investors are willing to pay $2.4 for every $1 of sales the company generates. In comparison, Eli Lilly and Company has a much higher Price-to-Sales Ratio of $17.5 for every $1 of sales. This suggests that investors value Eli Lilly's sales more highly than GSK's sales.

GSK Gsk Plc-spon Adr. Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$39.0B	↑ 2.1%
Net Income	$4.6B	↑ 136.49%
Net Profit Margin	11.75%	↑ 6.67%

	FY19	Y/Y Change
Revenue	$44.2B	↑ 9.52%
Net Income	$6.1B	↑ 28.21%
Net Profit Margin	13.76%	↑ 2.01%

	FY20	Y/Y Change
Revenue	$45.8B	↑ 1.02%
Net Income	$7.7B	↑ 23.77%
Net Profit Margin	16.86%	↑ 3.1%

	FY21	Y/Y Change
Revenue	$45.4B	↑ 0.04%
Net Income	$5.8B	↓ 23.73%
Net Profit Margin	12.85%	↓ 4.01%

	FY22	Y/Y Change
Revenue	$35.7B	↓ 14.04%
Net Income	$6.0B	↑ 12.22%
Net Profit Margin	16.78%	↑ 3.93%

	FY23	Y/Y Change
Revenue	$38.4B	↑ 3.42%
Net Income	$6.2B	↑ 0.14%
Net Profit Margin	16.25%	↓ 0.53%

	Q2 FY23	Q/Q Change
Revenue	$10.3B	↑ 17.21%
Net Income	$1.8B	↓ 1.74%
Net Profit Margin	17.97%	↓ 3.47%

	Q3 FY23	Q/Q Change
Revenue	$10.0B	↓ 1.17%
Net Income	$434.4M	↓ 76.09%
Net Profit Margin	4.35%	↓ 13.62%

	Q4 FY23	Q/Q Change
Revenue	$10.2B	↑ 0.0%
Net Income	$443.1M	↑ 0.0%
Net Profit Margin	4.35%	↑ 0.0%

	Q1 FY24	Q/Q Change
Revenue	$9.4B	↓ 8.56%
Net Income	$1.3B	↑ 198.86%
Net Profit Margin	14.21%	↑ 9.86%

	Q2 FY24	Q/Q Change
Revenue	$10.0B	↑ 7.08%
Net Income	$1.5B	↑ 12.14%
Net Profit Margin	14.88%	↑ 0.67%

	Q3 FY24	Q/Q Change
Revenue	$8.0B	↑ 1.62%
Net Income	$-58.0M	↓ 104.94%
Net Profit Margin	-0.72%	↓ 15.6%

	FY18	Y/Y Change
Profit	$26.1B	↑ 3.71%

	FY19	Y/Y Change
Profit	$28.7B	↑ 6.37%

	FY20	Y/Y Change
Profit	$30.1B	↑ 2.3%

	FY21	Y/Y Change
Profit	$29.9B	↑ 0.52%

	FY22	Y/Y Change
Profit	$24.1B	↓ 12.18%

	FY23	Y/Y Change
Profit	$27.6B	↑ 10.08%

	Q2 FY23	Q/Q Change
Profit	$7.4B	↑ 17.31%

	Q3 FY23	Q/Q Change
Profit	$7.1B	↓ 2.74%

	Q4 FY23	Q/Q Change
Profit	$7.2B	↑ 0.0%

	Q1 FY24	Q/Q Change
Profit	$6.9B	↓ 5.04%

	Q2 FY24	Q/Q Change
Profit	$7.4B	↑ 6.95%

	Q3 FY24	Q/Q Change
Profit	$5.6B	↓ 3.24%

	FY18	Y/Y Change
Operating Cash Flow	$10.7B	↑ 21.73%
Investing Cash Flow	$-2.0B	↑ 7.62%
Financing Cash Flow	$-8.1B	↑ 0.14%

	FY19	Y/Y Change
Operating Cash Flow	$10.5B	↓ 4.76%
Investing Cash Flow	$-7.0B	↑ 244.75%
Financing Cash Flow	$-2.4B	↓ 71.2%

	FY20	Y/Y Change
Operating Cash Flow	$11.3B	↑ 5.25%
Investing Cash Flow	$2.9B	↓ 140.36%
Financing Cash Flow	$-13.6B	↑ 450.65%

	FY21	Y/Y Change
Operating Cash Flow	$10.6B	↓ 5.79%
Investing Cash Flow	$-2.4B	↓ 182.23%
Financing Cash Flow	$-10.1B	↓ 25.1%

	FY22	Y/Y Change
Operating Cash Flow	$9.0B	↓ 6.9%
Investing Cash Flow	$-10.7B	↑ 393.64%
Financing Cash Flow	$1.0B	↓ 110.84%

	FY23	Y/Y Change
Operating Cash Flow	$8.6B	↓ 8.58%
Investing Cash Flow	$-2.0B	↓ 81.82%
Financing Cash Flow	$-7.1B	↓ 785.42%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$1.7B	↑ 2366.04%
Investing Cash Flow	$-1.2B	↑ 136.27%
Financing Cash Flow	$39.1M	↓ 109.75%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$2.7B	↑ 69.24%
Investing Cash Flow	$-609.4M	↓ 49.07%
Financing Cash Flow	$-2.2B	↓ 5783.87%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$3.8B	↑ 34.31%
Investing Cash Flow	$339.3M	↓ 154.58%
Financing Cash Flow	$-4.2B	↑ 87.63%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$1.2B	↓ 68.39%
Investing Cash Flow	$-189.4M	↓ 155.6%
Financing Cash Flow	$-1.3B	↓ 70.08%

Gsk Plc-spon Adr. Technicals Summary

Sell

Neutral

Buy

Gsk Plc-spon Adr. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Gsk Plc-spon Adr. (GSK) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Gsk Plc-spon Adr.	10.56%	-13.3%	-12.33%	-30.74%	-29.47%
Eli Lilly And Company	15.8%	-8.36%	13.45%	265.12%	532.01%
Johnson & Johnson	9.92%	-2.71%	-0.48%	-0.91%	9.44%
Merck & Co. Inc.	-8.36%	-24.8%	-32.17%	15.44%	7.81%
Novo Nordisk A/s	3.93%	-38.86%	-32.75%	68.76%	173.3%
Abbvie Inc	18.72%	1.69%	13.65%	38.0%	115.68%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Gsk Plc-spon Adr.	23.27	23.27	0.77	4.26	0.23	0.07	0.04	3.35
Eli Lilly And Company	74.56	74.56	0.87	23.1	0.84	0.14	0.01	15.83
Johnson & Johnson	27.27	27.27	1.0	10.55	0.2	0.08	0.03	29.7
Merck & Co. Inc.	12.7	12.7	0.07	8.99	0.42	0.11	0.04	17.58
Novo Nordisk A/s	26.23	26.23	1.2	0.0	0.81	0.22	0.02	32.31
Abbvie Inc	82.57	82.57	2.63	12.26	0.62	0.08	0.03	1.88

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Gsk Plc-spon Adr.	Buy	$74.6B	-29.47%	23.27	8.21%
Eli Lilly And Company	Buy	$784.2B	532.01%	74.56	23.51%
Johnson & Johnson	Buy	$380.1B	9.44%	27.27	15.84%
Merck & Co. Inc.	Buy	$216.5B	7.81%	12.7	26.67%
Novo Nordisk A/s	Buy	$366.2B	173.3%	26.23	34.78%
Abbvie Inc	Buy	$348.4B	115.68%	82.57	7.59%

Gsk Plc-spon Adr. Dividend announcements

Gsk Plc-spon Adr. Dividends March, 2025
In the quarter ending March,2025. Gsk Plc-spon Adr. has declared dividend of $0.40
Read More

About Gsk Plc-spon Adr.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.

Organization	Gsk Plc-spon Adr.
Employees	0
CEO	Ms. Sally Jackson
Industry	Health Technology

Management People of Gsk Plc-spon Adr.

Name	Title
Ms. Emma Natasha Walmsley	CEO & Director
Ms. Julie Belita Brown A.C.A.	CFO & Executive Director
Ms. Shobie Ramakrishnan	Chief Digital & Technology Officer
Mr. Tony Wood	Chief Scientific Officer and Head of R&D
Mr. Nick Stone	SVP & Head of Investor Relations
Mr. James Ford	Senior VP & Group General Counsel of Legal & Compliance
Ms. Sally Jackson	Senior Vice President of Global Communications & CEO Office
Mr. David Simon Redfern BSc (Hons), CA	President of Corporate Development
Ms. Diana Conrad	Chief People Officer
Mr. Philip C. Thomson	President of Global Affairs

Important FAQs about investing in GSK Stock from India :

What is Gsk Plc-spon Adr. share price today?

Gsk Plc-spon Adr. share price today stands at $36.96, Open: $36.72 ; Previous Close: $36.54 ; High: $37.22 ; Low: $36.63 ; 52 Week High: $45.93 ; 52 Week Low: $31.72.

The stock opens at $36.72, after a previous close of $36.54. The stock reached a daily high of $37.22 and a low of $36.63, with a 52-week high of $45.93 and a 52-week low of $31.72.

Can Indians buy Gsk Plc-spon Adr. shares?

Yes, Indians can invest in the Gsk Plc-spon Adr. (GSK) from India.

With INDmoney, you can buy Gsk Plc-spon Adr. at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Gsk Plc-spon Adr. at zero transaction cost.

How can I buy Gsk Plc-spon Adr. shares from India?

It is very easy to buy Gsk Plc-spon Adr. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Gsk Plc-spon Adr. (GSK) be purchased?

Yes, you can buy fractional shares of Gsk Plc-spon Adr. with INDmoney app.

What are the documents required to start investing in Gsk Plc-spon Adr. stocks?

To start investing in Gsk Plc-spon Adr., You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.